Compare FIVN & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIVN | NUVB |
|---|---|---|
| Founded | 2001 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2014 | 2020 |
| Metric | FIVN | NUVB |
|---|---|---|
| Price | $32.90 | $6.91 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 8 |
| Target Price | ★ $26.06 | $11.38 |
| AVG Volume (30 Days) | 3.4M | ★ 5.9M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 364.71 | 71.56 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,149,088,000.00 | $62,902,000.00 |
| Revenue This Year | $11.39 | $203.82 |
| Revenue Next Year | $10.00 | $58.18 |
| P/E Ratio | $129.20 | ★ N/A |
| Revenue Growth | 10.28 | ★ 698.96 |
| 52 Week Low | $13.29 | $2.84 |
| 52 Week High | $34.58 | $9.75 |
| Indicator | FIVN | NUVB |
|---|---|---|
| Relative Strength Index (RSI) | 61.21 | 58.62 |
| Support Level | $17.59 | $5.28 |
| Resistance Level | $34.58 | $8.95 |
| Average True Range (ATR) | 2.01 | 0.38 |
| MACD | -0.10 | 0.03 |
| Stochastic Oscillator | 73.51 | 60.88 |
Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.